Tumor protein p53 (TP53) R248Q neoantigen peptide presented by HLA-A*11:01 (TP53-R248Q/HLA-A*11:01)

The Tumor protein p53 (TP53) R248Q neoantigen peptide presented by HLA-A*11:01 is a highly specific molecular target for cancer immunotherapy, particularly in the context of T-cell receptor (TCR) based therapies. TP53 is a master tumor suppressor, and the R248Q substitution is a frequent hotspot mutation that occurs in the DNA-binding domain, contributing to oncogenesis in various solid tumors such as colorectal, lung, and ovarian cancers (Lo et al., 2019). This mutation creates a unique amino acid sequence that, when processed into a short peptide and loaded onto the Human Leukocyte Antigen (HLA) allele A*11:01, forms a neoantigenic complex on the surface of malignant cells. Because this complex is absent on healthy cells, it serves as an ideal target for TCR-engineered T cells (TCR-T) and neoantigen vaccines, which can selectively eliminate tumor cells while minimizing damage to normal tissues (Malekzadeh et al., 2019). Current clinical research focuses on identifying and validating high-affinity TCRs that can recognize this specific pMHC complex to treat patients who carry both the R248Q mutation and the HLA-A*11:01 genotype (Deniger et al., 2018).

Other names

p53 R248Q neoantigenHLA-A*11:01-restricted TP53 R248Q peptidep53-R248Q/HLA-A11 complexTumor protein p53 R248Q mutant peptide

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex leading to cytotoxic T-lymphocyte (CTL) activation and tumor cell lysis.